NeoGenomics Q3 Revenue Jumps 11.9% to $187.8M, Q4 Revenue Forecast at $188.3M
NeoGenomics posted Q3 revenues of $187.8M, 11.9% YoY growth, exceeding estimates by 2.1%, while analysts forecast Q4 revenue of $188.3M, up 9.5% YoY and EPS of $0.04. The company missed estimates three times in two years and trades below its $14.56 average analyst target after a 10% drop last month.
1. Q3 Performance
NeoGenomics delivered $187.8M in revenue for the third quarter, representing an 11.9% year-on-year increase and exceeding revenue estimates by 2.1%. Adjusted EPS met analyst expectations, underscoring consistent operational execution amid a challenging healthcare environment.
2. Q4 Expectations
Analysts project Q4 revenue of $188.3M, a 9.5% year-on-year rise, alongside adjusted EPS of $0.04 per share. This forecasted growth rate is modestly below the 10.6% increase recorded in the same quarter last year.
3. Peer Comparison
Healthcare peers Quest and DaVita reported Q4 revenue growth of 7.1% and 9.9%, beating estimates by 1.9% and 3.2% respectively. Their shares rallied 9.4% and 21.2% post-results, highlighting potential upside if NeoGenomics delivers in line with projections.
4. Stock Trend and Valuation
NeoGenomics shares have slid 10% over the past month and currently trade below the $14.56 average analyst price target. Historical volatility from tariff and tax concerns, coupled with three revenue-estimate misses in two years, underscores investor caution ahead of the earnings release.